

August 29, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Update on entering into a binding agreement for transfer of shares of CuraTeQ Biologics s.r.o., by Helix Healthcare B.V., to Curateq Biologics B.V., wholly owned subsidiaries of the Company

Ref: Our letter dated July 30, 2025

Further to the above mentioned letter dated July 30, 2025, whereby we had informed that a binding agreement had been entered into on July 29, 2025, for transfer of the entire shares of CuraTeQ Biologics s.r.o., held by Helix Healthcare B.V., to Curateq Biologics B.V., by August 31, 2025, we inform you that pending receipt of updated business register from authorities in The Netherlands reflecting the share transfer, the share transfer will be completed on or before September 30, 2025.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.